Combination Therapy using Co-encapsulated Resveratrol and Paclitaxel in Liposomes for Drug Resistance Reversal in Breast Cancer Cells in vivo
Open Access
- 7 March 2016
- journal article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 6 (1), 22390
- https://doi.org/10.1038/srep22390
Abstract
Multidrug resistance (MDR) is a major impediment to cancer treatment. A promising strategy for treating MDR is the joint delivery of combined anticancer agents to tumor cells in a single nanocarrier. Here, for the first time, Resveratrol (Res) was co-encapsulated with paclitaxel (PTX) in a PEGylated liposome to construct a carrier-delivered form of combination therapy for drug-resistant tumors. The composite liposome had an average diameter of 50 nm with encapsulated efficiencies of above 50%. The studies demonstrated that the composite liposome could generate potent cytotoxicity against the drug-resistant MCF-7/Adr tumor cells in vitro and enhance the bioavailability and the tumor-retention of the drugs in vivo. Moreover, systemic therapy with the composite liposome effectively inhibited drug-resistant tumor in mice (p < 0.01), without any notable increase in the toxicity. These results suggested that the co-delivery of Res and a cytotoxic agent in a nanocarrier may potentially improve the treatment of drug-resistant tumors.Keywords
This publication has 39 references indexed in Scilit:
- The dynamics of drug resistance: A mathematical perspectiveDrug Resistance Updates, 2012
- The Phytoalexin Resveratrol Regulates the Initiation of Hypersensitive Cell Death in Vitis CellPLOS ONE, 2011
- Enabling Anticancer Therapeutics by Nanoparticle Carriers: The Delivery of PaclitaxelInternational Journal of Molecular Sciences, 2011
- Heterogeneity Maintenance in Glioblastoma: A Social NetworkCancer Research, 2011
- Nanoparticle PEGylation for imaging and therapyNanomedicine, 2011
- Nanomedicinal strategies to treat multidrug-resistant tumors: current progressNanomedicine, 2010
- Circumventing Tumor Resistance to Chemotherapy by NanotechnologyPublished by Springer Science and Business Media LLC ,2009
- Combination of antiangiogenesis with chemotherapy for more effective cancer treatmentMolecular Cancer Therapeutics, 2008
- Multi-functional nanocarriers to overcome tumor drug resistanceCancer Treatment Reviews, 2008
- Combination of tunicamycin with anticancer drugs synergistically enhances their toxicity in multidrug-resistant human ovarian cystadenocarcinoma cellsCancer Cell International, 2007